Bukwang Pharmaceutical (003000.KS) Earnings Analysis

Bukwang Pharmaceutical (003000.KS) has no confirmed upcoming earnings date. Trailing P/E 66.38.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 003000.KS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 003000.KS. This page updates as the calendar is published.

003000.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-2011.93 KRWn/an/an/a
2026-02-0423.43 KRWn/an/an/a
2025-10-2011 KRWn/an/an/a
2025-07-2893.89 KRWn/an/an/a
2025-02-0626.99 KRWn/an/an/a
2024-07-25-50.52979 KRWn/an/an/a

003000.KS valuation and analyst view

Trailing P/E66.38
Trailing EPS91.035 KRW
Price / book1.18
Dividend yield3.11%
Market cap369.01B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Bukwang Pharmaceutical (003000.KS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 003000.KS. This page updates as the calendar is published.

Did 003000.KS beat earnings last quarter?

Consensus estimate data was not available for 003000.KS's 2026-04-20 report.

What is 003000.KS's current P/E ratio and EPS?

003000.KS trades at a trailing P/E of 66.38 on trailing EPS of 91.03531526735532 KRW.

What do analysts rate 003000.KS?

003000.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.